Age

18–70

Sex

FEMALE

Healthy volunteers

Not accepted

Provision of informed consent
Pathological confirmation of breast cancer
ER(+) and/or PR(+).
Post-menopausal woman
Age≤70 years old
Breast conservative surgery with axillary dissection or staging by either sentinel nodes biopsy or axillary sampling
Post-mastectomy patients with T1-T2 and N1-N3, or T3-T4 with any N Negative surgical margins
Karnofsky≥70
Laboratory criteria:
* PLT≥100\*109/L
* WBC≥4000/mm3
* HGB≥10g/dl
* ALT and AST\<2\*ULN
No presence of metastatic disease
No other malignant tumour

Presence of metastatic disease.
T1, T2, N0 with mastectomy
Non-infiltrative breast carcinoma underwent mastectomy
Other malignant tumor (concurrent or previous).
Positive surgical margins.
Patients with demonstrated hypersensitivity to Arimidex or any excipient.
Patients with severe renal impairment (creatinine clearance less than 20 ml/min).
Patients with moderate or severe hepatic disease.
Oestrogen-containing therapies should not be co-administered with Arimidex as they would negate its pharmacological action.
Not able or willing to sign informed consent
Autoimmune diseases including scleroderma, systemic lupus erythematosus and so on

Study of Arimidex and Radiotherapy Sequencing